本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-046 桂林莱茵生物科技股份有限公司 关于召开 2025 年第一次临时股东会的通知 2025 年 8 月 20 日，桂林莱茵生物科技股份有限公司（以下简称"公司"） 第七届董事会第六次会议审议通过了《关于召开 2025 年第一次临时股东会的议 案》，现将本次股东会的有关事项公告如下： 一、召开会议的基本情况 1、会议届次：2025 年第一次临时股东会 2、会议召集人：公司第七届董事会，公司第七届董事会第六次会议决议召 开本次股东会。 3、会议召开的合法、合规性： 本次股东会的召集、召开符合有关法律、行政法规、部门规章、规范性文件、 深圳证券交易所业务规则和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议的召开时间：2025 年 9 月 9 日下午 15:00； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为 2025 年 9 月 9 日上午 9:15—9：25，9：30—11:30 以及下午 13 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-043 二、监事会会议审议情况 经认真的讨论和审议，会议以记名投票方式表决，形成决议如下： 1、会议以 3 票同意、0 票反对、0 票弃权审议通过《关于缩减部分募集资金 投资规模、结项募投项目并将节余募集资金永久补充流动资金的议案》； 监事会认为，本次缩减部分募投项目的投资规模、结项募投项目并将节余募 集资金永久补充流动资金是基于目前公司实际情况及合理使用募集资金所作出 的决策。公司将节余的募集资金及利息永久补充流动资金，有利于提高募集资金 使用效率，降低公司财务成本，符合公司及全体股东的利益，不存在损害公司和 股东尤其是中小股东的合法权益的情形。 公司监事会一致同意缩减部分募投项目的投资规模、结项募投项目并将节余 募集资金永久补充流动资金的议案。 具体内容详见公司同日刊登于《中国证券报》《证券时报》《上海证券报》《证 券日报》和巨潮资讯网的《关于缩减部分募集资金投资规模、结项募投项目并将 桂林莱茵生物科技股份有限公司 第七届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 ...

证券代码：002166 证券简称：莱茵生物 公告编号：2025-042 桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司 第七届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林莱茵生物科技股份有限公司（以下简称"公司"）关于召开第七届董事会第 六次会议的通知于 2025 年 8 月 17 日以短信、即时通讯工具及电子邮件的方式发 出，会议于 2025 年 8 月 20 日上午 11：00 以通讯方式召开。本次会议应参与表决 董事 7 名，实参与表决董事 7 名，公司全体监事、高级管理人员列席了会议。会 议由董事长谢永富先生主持，会议的召开符合《中华人民共和国公司法》（以下 简称"《公司法》"）和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 经充分的讨论和审议，会议以记名投票方式表决，形成如下决议： 1、会议以 7 票同意、0 票反对、0 票弃权审议通过《关于缩减部分募集资金 投资规模、结项募投项目并将节余募集资金永久补充流动资金的议案》； 为满足未来对流动资金的需求，提高募集资金 ...

Group 1 - The chemical products sector increased by 0.71% on August 21, with Feilu Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] - Notable gainers in the chemical products sector included Feilu Co., Ltd. with a closing price of 12.85, up 10.40%, and Boyuan Co., Ltd. with a closing price of 44.84, up 10.25% [1] Group 2 - The chemical products sector experienced a net outflow of 449 million yuan from institutional funds, while retail investors saw a net inflow of 500 million yuan [2] - The top individual stock performers in terms of net inflow included Wanhua Chemical with a net inflow of 4.24 billion yuan, while retail investors showed significant outflows in several stocks [3] - The overall trading volume and turnover in the chemical products sector reflected mixed investor sentiment, with some stocks experiencing substantial declines [2][3]

Core Insights - The approval status of RebM2, a steviol glycoside, in the domestic market has garnered investor attention, with the company actively pushing for subsequent approval processes after the public consultation phase ended on August 14 [1] - RebM2 has received GRAS certification from the FDA, allowing it to be legally sold in the U.S. food and beverage market, potentially becoming a new profit growth point for the company [1] - RebM2, developed through enzyme conversion, offers superior sweetness characteristics, a purer taste, better stability, and improved solubility compared to existing rare monomer components, making it a promising natural sweetener [1] Industry Developments - The industrialization of RM2 is seen as a milestone in the evolution of steviol glycosides, with RM2 being approximately 200 times sweeter than sucrose and exhibiting a favorable sweetness release curve [2] - RM2's formulation can optimize costs and enhance taste in reduced-sugar recipes, breaking through traditional limitations and expanding the market boundaries for steviol glycosides [2] - The enzyme conversion process has significantly improved the yield of rare monomers to over 75%, marking a shift from resource-dependent to technology-driven production in the natural sweetener industry [2] Company Innovations - RM2 is part of a broader strategy in synthetic biology, with the company also achieving breakthroughs in the complete synthesis of monk fruit sweet glycosides and advancements in the field of left-handed β-galactomannan [3] - The enzyme conversion method demonstrates the feasibility and application value of synthetic biology in the plant extract sector, enhancing supply chain stability and aligning with sustainable development goals [3] - The company is exploring a strategic transformation towards becoming a technology-driven health consumption technology enterprise through a dual approach of natural extraction and biological synthesis [3]

Group 1 - The core viewpoint of the article indicates that the company, 莱茵生物 (Rhein Biotech), primarily focuses on functional ingredients and currently has no plans for large-scale production of natural pigments [1] Group 2 - The company engages in investor interactions to clarify its business direction and product focus [1] - The absence of plans for natural pigment production suggests a strategic emphasis on its existing product lines rather than diversifying into new areas at this time [1]

Group 1 - The company has a certain amount of CBD inventory [1] - The factory in Indiana, USA, has the production capacity for industrial hemp extracts, allowing the company to respond promptly to market demands [1]

Group 1 - The core viewpoint is that if the FDA in the United States cancels synthetic dyes, there will be a significant increase in demand for natural dyes, but the company currently has no plans for large-scale production of natural dyes [2][3] - The company primarily focuses on functional ingredients and does not have immediate plans to adjust production to meet potential demand for natural dyes [2]

Core Viewpoint - The company is advancing the approval and market entry of its newly developed steviol glycoside, RebM2, which has received GRAS certification in the U.S. and is nearing domestic approval in China, indicating significant potential for growth in the natural sweetener market [1][2][3]. Group 1: Product Development and Market Potential - RebM2 is a rare, high-value steviol glycoside that meets the increasing demand for low-calorie, high-sweetness solutions in the context of global sugar reduction initiatives [2]. - The product offers a sweetness level 150 to 200 times that of sucrose, with zero calories and a favorable taste profile, addressing the limitations of traditional steviol glycosides [2][3]. - The company has successfully improved the production efficiency and cost-effectiveness of RebM2 through enzyme conversion methods, enhancing its solubility and stability [3]. Group 2: Strategic Importance and Future Plans - The completion of the public consultation phase for RebM2 in China is a crucial step for the company to accelerate its market promotion and sales efforts [3]. - The company plans to focus on the deep development of RebM2, aiming to innovate applications and expand its product matrix [4]. - The synthetic biology workshop is set to commence operations in September 2024, enabling mass production of RebM2 [3].

Core Insights - The company has developed RebM2, a natural sweetener that overcomes the taste limitations of traditional steviol glycosides, offering "zero calories, high safety, and a taste close to sucrose" as its main advantages [1]. Product Development - RebM2 has successfully passed the public announcement period for new food additives in China, distinguishing itself from other steviol glycosides [3]. - The product can be combined with low-intensity sweeteners like erythritol and allulose, as well as high-intensity sweeteners such as RA and monk fruit glycosides, to create customized sweetening solutions [1]. Market Application - RebM2 has been validated in various application scenarios, including dairy products, beverages, baking, and seasonings, indicating a promising future market potential [1].